Search: onr:"swepub:oai:gup.ub.gu.se/163572" > Lapatinib with tras...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04261naa a2201177 4500 | |
001 | oai:gup.ub.gu.se/163572 | |
003 | SwePub | |
008 | 240528s2012 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/1635722 URI |
024 | 7 | a https://doi.org/10.1016/S0140-6736(11)61847-32 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Baselga, José4 aut |
245 | 1 0 | a Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. |
264 | 1 | c 2012 |
520 | a The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Administration | |
653 | a Oral | |
653 | a Adult | |
653 | a Aged | |
653 | a Antibodies | |
653 | a Monoclonal | |
653 | a Humanized | |
653 | a administration & dosage | |
653 | a adverse effects | |
653 | a Antineoplastic Combined Chemotherapy Protocols | |
653 | a adverse effects | |
653 | a therapeutic use | |
653 | a Breast Neoplasms | |
653 | a chemistry | |
653 | a drug therapy | |
653 | a pathology | |
653 | a surgery | |
653 | a Chemotherapy | |
653 | a Adjuvant | |
653 | a Diarrhea | |
653 | a chemically induced | |
653 | a Drug Administration Schedule | |
653 | a Female | |
653 | a Humans | |
653 | a Infusions | |
653 | a Intravenous | |
653 | a Liver | |
653 | a drug effects | |
653 | a metabolism | |
653 | a Middle Aged | |
653 | a Neoadjuvant Therapy | |
653 | a methods | |
653 | a Paclitaxel | |
653 | a administration & dosage | |
653 | a adverse effects | |
653 | a Quinazolines | |
653 | a administration & dosage | |
653 | a adverse effects | |
653 | a Receptor | |
653 | a erbB-2 | |
653 | a analysis | |
653 | a antagonists & inhibitors | |
653 | a Treatment Outcome | |
653 | a Tumor Markers | |
653 | a Biological | |
653 | a analysis | |
653 | a antagonists & inhibitors | |
700 | 1 | a Bradbury, Ian4 aut |
700 | 1 | a Eidtmann, Holger4 aut |
700 | 1 | a Di Cosimo, Serena4 aut |
700 | 1 | a de Azambuja, Evandro4 aut |
700 | 1 | a Aura, Claudia4 aut |
700 | 1 | a Gómez, Henry4 aut |
700 | 1 | a Dinh, Phuong4 aut |
700 | 1 | a Fauria, Karine4 aut |
700 | 1 | a Van Dooren, Veerle4 aut |
700 | 1 | a Aktan, Gursel4 aut |
700 | 1 | a Goldhirsch, Aron4 aut |
700 | 1 | a Chang, Tsai-Wang4 aut |
700 | 1 | a Horváth, Zsolt4 aut |
700 | 1 | a Coccia-Portugal, Maria4 aut |
700 | 1 | a Domont, Julien4 aut |
700 | 1 | a Tseng, Ling-Min4 aut |
700 | 1 | a Kunz, Georg4 aut |
700 | 1 | a Sohn, Joo Hyuk4 aut |
700 | 1 | a Semiglazov, Vladimir4 aut |
700 | 1 | a Lerzo, Guillermo4 aut |
700 | 1 | a Palacova, Marketa4 aut |
700 | 1 | a Probachai, Volodymyr4 aut |
700 | 1 | a Pusztai, Lajos4 aut |
700 | 1 | a Untch, Michael4 aut |
700 | 1 | a Gelber, Richard D4 aut |
700 | 1 | a Piccart-Gebhart, Martine4 aut |
700 | 1 | a Holmberg, Stig B,d 1946u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för kirurgi4 org |
773 | 0 | t Lancetg 379:9816, s. 633-40q 379:9816<633-40x 1474-547X |
856 | 4 8 | u https://gup.ub.gu.se/publication/163572 |
856 | 4 8 | u https://doi.org/10.1016/S0140-6736(11)61847-3 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.